Image by Sasun Bughdaryan

March 25, 2021

Experimental and Clinical Psychopharmacology

We are happy to announce that our newest paper was just published in the Journal of Experimental and Clinical Psychopharmacology.  We recently completed analyses of medical cannabis (MC) patients who report chronic pain as their primary indication for MC use and compared them to a pilot sample of treatment-as-usual (TAU) patients who do not use MC. Results revealed that after initiation of MC use, MC patients generally exhibited lower self-reported pain ratings, which were accompanied by improvements on measures of clinical state, quality of life, and sleep - a pattern not observed in the TAU group. Among MC patients , increased THC exposure was related to pain-related improvement, while CBD exposure was related to improved mood. 

Image by David Gabrić

October 13, 2016

Frontiers in Pharmacology

The first publication from the MIND program was published today in Frontiers in Pharmacology! After 3 months of medical cannabis treatment, medical cannabis patients demonstrated improvements in clinical state,  cognition, quality of life and other health-related measures. Decreased use of conventional pharmaceutical medications was also noted among study patients.

drug test cup 2.jpg

November 4, 2020

JAMA Psychiatry

We are excited to share that a set of findings from the open label phase of our clinical trial assessing a full-spectrum, high-CBD/low-THC product were recently published in JAMA Psychiatry! These findings show that 50% of individuals enrolled in the clinical trial tested positive for THC on a urinary drug assay after using the the sublingual solution for four weeks. Positive THC findings occurred in some individuals although the study product contains far less THC than is allowable for hemp-based products in the US. More research is needed to understand which variables may contribute to positive findings in some individuals, but not others. 

grass might be greener.jpg

January 22, 2018

Frontiers in Pharmacology

We are pleased to announce that Frontiers has just published our second paper from the MIND program. This marks the first neuroimaging study in medical cannabis patients, documenting potential normalization of brain activity during the Multi-Source Interference Task (MSIT), a measure of executive function, after three months of medical cannabis treatment.